A new study in BMJ Global Health across 13 middle- and high-income countries reveals that 25% of patients reported symptoms of long COVID after symptomatic COVID-19, and long COVID is significantly more prevalent in participants from less wealthy nations and in patients of Arab or North African ethnicity.
A pair of new studies finds no significant benefit of the antiviral drug nirmatrelvir-ritonavir (Paxlovid) in alleviating the symptoms of adult long-COVID patients or in preventing the development of the condition in adolescents.
COVID-19 vaccination slashed the risk of experiencing prolonged symptoms by about 27% in fully vaccinated adults who were later infected, estimates a European Centre for Disease Prevention and Control (ECDC) systematic review of 12 studies.
